1. Home
  2. PIK3CA-Related Overgrowth Spectrum

PIK3CA-Related Overgrowth Spectrum
Symptoms, Doctors, Treatments, Advances & More

Find a DoctorCondition OverviewLatest AdvancesClinical TrialsTreatments

PIK3CA-Related Overgrowth Spectrum Overview

  • Definition
  • Symptoms
  • Treatments
  • Top Doctors
  • Clinical Trials
  • Latest Advances
Save information for later
Sign Up

Learn About PIK3CA-Related Overgrowth Spectrum

What is the definition of PIK3CA-Related Overgrowth Spectrum?
PIK3CA-related overgrowth spectrum is a term used to describe a group of rare genetic disorders that cause an overgrowth of body parts. This overgrowth of body parts is caused by mutations in the PIK3CA gene that assists in cell growth.
What are the symptoms of PIK3CA-Related Overgrowth Spectrum?
Symptoms of PIK3CA-related overgrowth spectrum disorders depend on the subtype. Symptoms of PIK3CA-related overgrown spectrum disorders can include overgrowth of muscles, fingers, toes, arms, legs, trunk, or brain; intellectual disability; autism; language disorders; seizures; blood clots; lip malformation; face and neck malformation; fatty tissue overgrowth; vascular malformations; moles; bone abnormalities; port-wine stains; prominent veins; pulmonary embolism; scoliosis; spinal cord compression; kidney abnormalities; gastrointestinal bleeding; genitourinary tract bleeding; heart failure; extra fingers or toes; lipomas; enlarged teeth; enlarged tongue; neuromas; lymphatic malformations; and nerve disorders.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for PIK3CA-Related Overgrowth Spectrum?
Treatment for PIK3CA-related overgrowth spectrum disorders depends on the subtype and the symptoms. Treatments for PIK3CA-related overgrowth spectrum disorders may include targeted therapy, such as alpelisib; laser ablation; sclerotherapy; anticoagulation therapy; surgery; orthotics; brain shunt placement; anti-seizure medications; physical, occupational, and speech therapy; and special education.
Who are the top PIK3CA-Related Overgrowth Spectrum Local Doctors?
Sibylle F. Loibl
Elite in PIK3CA-Related Overgrowth Spectrum
Sibylle F. Loibl
Elite in PIK3CA-Related Overgrowth Spectrum
Sibylle F. Loibl
Referral may be required
Martin Behaim Str 12, 
Neu Isenburg, HE, DE 

Sibylle Loibl practices practicing medicine in Neu Isenburg, Germany. Ms. Loibl is rated as an Elite expert by MediFind in the treatment of PIK3CA-Related Overgrowth Spectrum. She is also highly rated in 17 other conditions, according to our data. Her clinical expertise encompasses Breast Cancer, PIK3CA-Related Overgrowth Spectrum, Triple-Negative Breast Cancer, Breast Cancer in Men, and Mastectomy.

Fabrice Andre
Elite in PIK3CA-Related Overgrowth Spectrum
Fabrice Andre
Elite in PIK3CA-Related Overgrowth Spectrum
Fabrice Andre
Referral may be required

Gustave Roussy

Villejuif, FR 

Fabrice Andre practices practicing medicine in Villejuif, France. Mr. Andre is rated as an Elite expert by MediFind in the treatment of PIK3CA-Related Overgrowth Spectrum. He is also highly rated in 11 other conditions, according to our data. His clinical expertise encompasses Breast Cancer, PIK3CA-Related Overgrowth Spectrum, Triple-Negative Breast Cancer, Tissue Biopsy, and Mastectomy.

 
 
 
 
Learn about our expert tiers
Learn More
Funda Meric
Elite in PIK3CA-Related Overgrowth Spectrum
Dr. Funda Meric
General Surgery | Surgical Oncology
Elite in PIK3CA-Related Overgrowth Spectrum
Dr. Funda Meric
General Surgery | Surgical Oncology
Referral may be required

MD Anderson

2130 W Holcombe Blvd, Univ Of Tx M D Ande Life Sciences Plaza, 
Houston, TX 
713-592-5433
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Funda Meric is a General Surgeon and a Surgical Oncologist practicing medicine in Houston, Texas. Dr. Meric is rated as an Elite provider by MediFind in the treatment of PIK3CA-Related Overgrowth Spectrum. She is also highly rated in 18 other conditions, according to our data. Her clinical expertise encompasses PIK3CA-Related Overgrowth Spectrum, Breast Cancer, Cholangiocarcinoma (Bile Duct Cancer), Triple-Negative Breast Cancer, and Mastectomy.

View All Doctors
What are the latest PIK3CA-Related Overgrowth Spectrum Clinical Trials?
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Patients With Endocrine- Resistant Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer With Chromosome 8P Loss and Without a PIK3CA Mutation
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Patients With Endocrine- Resistant Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer With Chromosome 8P Loss and Without a PIK3CA Mutation
Enrollment Status: Recruiting
Publish Date: September 08, 2026
Intervention Type: Drug
Study Phase: Phase 2

Summary: A study to evaluate the efficacy and safety of triplet combination of inavolisib plus ribociclib and fulvestrant versus placebo plus ribociclib and fulvestrant in the first-line setting in participants with endocrine-therapy-resistant hormone receptor (HR)-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC).

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 2, Randomized, Open-Label Dose Optimization and Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY4064809 Combined With a CDK4/6 Inhibitor and Endocrine Therapy in Adults With HR+, HER2-Advanced Breast Cancer With a PIK3CA Mutation Who Received No Prior Treatment for Advanced Breast Cancer (PIKALO-2)
A Phase 2, Randomized, Open-Label Dose Optimization and Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY4064809 Combined With a CDK4/6 Inhibitor and Endocrine Therapy in Adults With HR+, HER2-Advanced Breast Cancer With a PIK3CA Mutation Who Received No Prior Treatment for Advanced Breast Cancer (PIKALO-2)
Enrollment Status: Recruiting
Publish Date: September 08, 2026
Intervention Type: Drug
Study Phase: Phase 3

Summary: The purpose of the study is to assess the efficacy and safety of the addition of Tersolisib (LY4064809/STX-478) to other anti-cancer drugs as first treatment for advanced hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Participants can remain in the study as long as the drug is helping the cancer without unbearable side effects.

View All Clinical Trials
What are the Latest Advances for PIK3CA-Related Overgrowth Spectrum?
State Changes and Stability Grading of Driver Genes in Non-small Cell Lung Cancer Based on Repeated NGS Testing
State Changes and Stability Grading of Driver Genes in Non-small Cell Lung Cancer Based on Repeated NGS Testing
Journal: Zhongguo fei ai za zhi = Chinese journal of lung cancer
Published: September 07, 2026
Effects of astragaloside Ⅰ on full-thickness skin defects in diabetic rats and its underlying mechanism
Effects of astragaloside Ⅰ on full-thickness skin defects in diabetic rats and its underlying mechanism
Journal: Zhonghua shao shang yu chuang mian xiu fu za zhi
Published: September 07, 2026
Tired of the same old research?
Check Latest Advances
Implementing liquid biopsy in HR+/HER2- metastatic breast cancer: challenges and opportunities.
Implementing liquid biopsy in HR+/HER2- metastatic breast cancer: challenges and opportunities.
Journal: Current opinion in oncology
Published: September 03, 2026
View All Latest Advances
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved